CD19 Mouse anti-Human, Monkey, Primate, DyLight 405, Clone: CVID3/429, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus Biologicals NBP261909V

Catalog No. NBP2-61909V

Description

CD19 Monoclonal antibody specifically detects CD19 in Human, Monkey, Primate samples. It is validated for Flow Cytometry, Immunocytochemistry, Immunofluorescence.

Specifications

• Antigen: CD19
• Clone: CVID3/429
• Dilution: Flow Cytometry, Immunocytochemistry/Immunofluorescence
• Format: Conjugated, Purified
• Gene Symbols: CD19
• Immunogen: Recombinant human CD19 protein
• Purification Method: Protein A or G purified
• Research Discipline: Adaptive Immunity, B Cell Development and Differentiation Markers, Cytokine Research, Immunology, Mesenchymal Stem Cell Markers, Myeloid derived Suppressor Cell, Signal Transduction, Stem Cell Lines, Stem Cell Markers
• Primary or Secondary: Primary
• Gene ID (Entrez): 930
• Target Species: Human, Monkey, Primate

• Applications: Flow Cytometry, Immunocytochemistry, Immunofluorescence
• Conjugate: DyLight 405
• Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
• Gene Alias: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19 antigen, CD19 molecule, CVID3, Differentiation antigen CD19, MGC12802, T-cell surface antigen Leu-12
• Host Species: Mouse
• Isotype: IgG1 Kappa
• Quantity: 0.1 ml
• Storage Requirements: Store at 4°C in the dark.
• Monoclonal or Polyclonal: Monoclonal
• Test Specificity: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms